The bill amends the Social Security Act to require the Comptroller General to study price‑related compensation and payment structures in the retail prescription drug supply chain and to report findings and recommendations to Congress within two years. The study must catalog the types, magnitude, prevalence, and drivers of arrangements that tie fees or payments to a drug’s price and analyze potential conflicts of interest and differences across market segments.
This matters because Congress would get an evidence base to evaluate whether common contract features—like fees calculated as a percentage of drug price or rebate‑aggregation practices—distort purchasing, formulary design, or distribution. The GAO’s findings could spur legislation or administrative action affecting PBMs, plan sponsors, pharmacies, manufacturers, and other intermediaries even though the bill itself does not impose new regulatory requirements on these entities.
At a Glance
What It Does
The bill adds a new subsection to 42 U.S.C. 1395w–152 directing the Comptroller General to study compensation and payment structures that are related to a prescription drug’s price across the retail supply chain. The GAO must examine types of price‑based fees, business models, affiliated vs. unaffiliated arrangements, conflicts of interest, trends over time, and factors driving the use of such structures.
Who It Affects
Entities in scope include pharmacy benefit managers (PBMs), Medicare Part D plan sponsors, drug wholesalers, pharmacies, manufacturers, pharmacy services administrative organizations (PSAOs), brokers, auditors, consultants, rebate aggregators and other service providers contracting with those parties. Congressional committees, CMS, state Medicaid programs, and industry stakeholders will be direct users of the report.
Why It Matters
The study creates a formal, Congress‑commissioned fact base on whether price‑linked payments create misaligned incentives in buying and formulary decisions—a central question in current drug pricing debates. Because the GAO report must include recommendations, its findings could catalyze targeted legislative or administrative reforms even though the bill does not itself change market rules.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a single new subsection into the Social Security Act requiring the Government Accountability Office to conduct a comprehensive study of compensation and payment arrangements that vary with a prescription drug’s price in the retail supply chain. The GAO’s assignment is broad: it must describe what these arrangements look like in practice (for example, fees set as a percentage of price, benchmarked payments, or rebate aggregation), measure how widespread they are, and report on their size and salient features.
The statute provides an explicit list of the actors the GAO should examine—PBMs, Part D plan sponsors, wholesalers, pharmacies, manufacturers, PSAOs, brokers/auditors/consultants who advise plan sponsors, and other service providers including rebate aggregators. Beyond cataloging arrangements, the GAO must describe primary business models used by each category, compare arrangements between affiliated and unaffiliated entities, identify potential conflicts of interest, and trace trends across market segments including comparisons with Medicaid where relevant.Practically, the GAO will have to assemble heterogeneous data: commercial contracts, fee schedules, claims and payment data from Part D and possibly state Medicaid programs, and interviews with market participants.
The statute gives the Comptroller General authority to make recommendations for legislation and administrative action, so the report is intended not just to inform but to guide potential policy responses. The deadline is firm: Congress must receive the report within two years of enactment.
The Five Things You Need to Know
The bill amends 42 U.S.C. 1395w–152 by adding a new subsection that mandates a GAO study of price‑related compensation and payment structures in the retail prescription drug supply chain.
GAO must analyze types, magnitude, prevalence, pricing benchmarks, and features of price‑linked fees—explicitly including fees calculated as a percentage of a drug’s price.
The statute lists the parties in scope: pharmacy benefit managers, Medicare Part D plan sponsors, wholesalers, pharmacies, manufacturers, PSAOs, brokers/auditors/consultants, and rebate aggregators (or similar negotiators/processors).
The GAO must compare arrangements between affiliated and unaffiliated entities, examine trends over time and across market segments (including comparisons to Medicaid), and identify factors driving use of these structures.
GAO must deliver a report to Congress with findings and recommendations for legislative and administrative action no later than two years after the bill’s enactment.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the act’s name as the "Prescription Drug Supply Chain Pricing Transparency Act." This is purely stylistic but signals congressional intent to frame the measure around transparency in pricing‑linked arrangements rather than imposing immediate regulatory change.
Where the study lives in federal law
The bill adds the study requirement as a new subsection of the Medicare Part D statutory provision governing plan requirements and contracts. Placing the mandate within this statute ties the study explicitly to Medicare Part D’s prescription drug market and gives Congress a clearer path to use the findings for Part D‑specific reforms, although the study’s scope extends beyond Part D participants to private market intermediaries and comparisons with Medicaid.
Required analytic topics and enumerated actors
Paragraph (1) directs the Comptroller General to investigate a defined set of issues: types and magnitude of price‑related compensation, primary business models for each class of intermediary, variation between affiliated and unaffiliated entities, conflicts of interest, temporal and cross‑market trends, and drivers of these arrangements. The bill lists specific actors the GAO must examine—PBMs, Part D plan sponsors, wholesalers, pharmacies, manufacturers, PSAOs, brokers/auditors/consultants, and other service providers like rebate aggregators—which narrows GAO’s universe and focuses data collection on commercially sensitive contract terms among these groups.
Timing and deliverables
The Comptroller General must submit the study results and any suggested legislative or administrative remedies to Congress within two years of enactment. The statutory language requires GAO to go beyond description to provide recommendations, which elevates the report from informational to policy‑oriented and increases the probability that the study will prompt follow‑up action by Congress or federal agencies.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Congressional finance and health oversight committees — receive a structured, government‑produced evidence base on price‑linked payment mechanics to inform targeted reforms in Part D and broader drug pricing oversight.
- Patient and consumer advocacy groups — gain authoritative documentation of whether price‑tied payments create perverse incentives that raise out‑of‑pocket costs or skew formulary choices, strengthening advocacy for legislative fixes.
- Independent pharmacies and smaller market participants — may benefit if the study exposes practices that disadvantage them (for example, percentage‑based fees that favor higher‑priced drugs), producing grounds for regulatory or contractual remedies.
- Academic and policy researchers — get a consolidated dataset and GAO analysis that can underpin further empirical work on market incentives and the impact of contractual arrangements on prices and access.
Who Bears the Cost
- PBMs, Part D plan sponsors, PSAOs, wholesalers, brokers, auditors, and rebate aggregators — will face time and resource costs responding to GAO information requests and possibly disclosing commercially sensitive contract terms.
- Manufacturers and pharmacies — may incur reputational and strategic costs if the GAO details price‑linked arrangements that become the basis for legislative or regulatory restrictions.
- CMS and state Medicaid agencies — could face political and operational pressure to act on GAO recommendations, potentially creating unfunded policy or oversight requirements.
- Private sector legal and compliance teams — may need to prepare for potential legislative or administrative changes that alter contract structures or require additional disclosures.
Key Issues
The Core Tension
The central tension is between transparency for public‑policy purposes and protection of commercially sensitive contracting information: exposing price‑related payment mechanics can illuminate misaligned incentives and enable corrective policy, but requiring disclosure risks revealing trade secrets, altering competitive dynamics, and imposing real compliance burdens on private parties—choices that have distributional effects and no uniformly 'correct' resolution.
The bill assigns a fact‑finding role to GAO but leaves open critical implementation questions that will shape the study’s utility. GAO will need access to granular, contract‑level commercial data—fee schedules, rebate arrangements, and internal pricing benchmarks—that parties typically guard as trade secrets.
While GAO can request documents and interviews, it cannot always compel disclosure from private firms, which could result in gaps or reliance on aggregated or redacted data. Those limitations matter for the precision of GAO’s estimates of magnitude and prevalence.
Methodologically, disentangling correlation from causation will be hard. The statute asks GAO to identify whether price‑linked fees create conflicts of interest (for example, incentives to favor higher‑price drugs), but observable associations between fee structures and outcomes like formulary placement do not, by themselves, prove causal channels.
GAO will have to combine contract analysis with outcomes data (claims, utilization, pricing changes) and qualitative interviews, and its conclusions will likely need caveats. The two‑year deadline concentrates resources but may force tradeoffs between breadth and depth—GAO could produce a timely, high‑level map or a narrower, more definitive analysis, but not both.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.